These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18595128)

  • 21. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype 2 patients].
    Jung EU; Park JH; Pae KI; Kang SW; Park SJ; Jee SR; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2007 Sep; 13(3):341-8. PubMed ID: 17898550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virological response.
    Pearlman BL; Ehleben C
    Hepatology; 2010 Oct; 52(4):1519-20; author reply 1520-1. PubMed ID: 20879035
    [No Abstract]   [Full Text] [Related]  

  • 24. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response.
    Buti M; Lurie Y; Zakharova NG; Blokhina NP; Horban A; Teuber G; Sarrazin C; Balciuniene L; Feinman SV; Faruqi R; Pedicone LD; Esteban R;
    Hepatology; 2010 Oct; 52(4):1201-7. PubMed ID: 20683847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.
    Pearlman BL; Ehleben C; Saifee S
    Hepatology; 2007 Dec; 46(6):1688-94. PubMed ID: 18046717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b.
    Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Hosokawa T; Arakawa T; Fujimori M
    J Med Virol; 2011 Jan; 83(1):101-7. PubMed ID: 21108345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The meaning of viral kinetics in the beginning of the pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C].
    Husa P; Slesinger P; Stroblová H; Svobodník A
    Vnitr Lek; 2006 Feb; 52(2):153-9. PubMed ID: 16623278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin.
    Nguyen MH; Trinh HN; Garcia R; Nguyen G; Lam KD; Keeffe EB
    Am J Gastroenterol; 2008 May; 103(5):1131-5. PubMed ID: 18477343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

  • 30. Response-guided therapy for acute hepatitis C: applying concepts from chronic treatment.
    McGowan CE; Dougherty KA; Fried MW
    Liver Int; 2011 Jul; 31(6):903-4. PubMed ID: 21645223
    [No Abstract]   [Full Text] [Related]  

  • 31. On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula.
    Saito H; Ebinuma H; Ojiro K; Wakabayashi K; Inoue M; Tada S; Hibi T
    World J Gastroenterol; 2010 Jan; 16(1):89-97. PubMed ID: 20039454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.
    Shiffman ML; Suter F; Bacon BR; Nelson D; Harley H; Solá R; Shafran SD; Barange K; Lin A; Soman A; Zeuzem S;
    N Engl J Med; 2007 Jul; 357(2):124-34. PubMed ID: 17625124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial.
    Shoeb D; Dearden J; Weatherall A; Bargery C; Moreea S; Alam S; White E; Vila X; Freshwater D; Ryder S; Mills PR; Alexander GJ; Forton D; Foster GR
    J Hepatol; 2014 Apr; 60(4):699-705. PubMed ID: 24291239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
    Patel MR; Mullen MP; Dieterich DT
    AIDS Read; 2006 Mar; 16(3):164, 168-9; discussion 168-9. PubMed ID: 16538956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
    Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
    AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of non-1 genotype chronic hepatitis C patients].
    Hrstić I; Ostojić R
    Acta Med Croatica; 2013 Oct; 67(4):339-43. PubMed ID: 24984334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
    Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
    J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
    Craxi A; Koutsounas S; Ogurtsov P; Chemello L; Maticic M; Torras J; Diago M; Tartaglione MT; Witthoeft T; Yu X; Faruqi R; Chaudhri E; Pedicone LD; Zuckerman E
    J Viral Hepat; 2012 Feb; 19(2):e120-5. PubMed ID: 22239509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When less may not be best--the challenge of individualising antiviral therapy for chronic hepatitis C infection.
    Knight V; Sievert W
    J Gastroenterol Hepatol; 2009 Mar; 24(3):330-2. PubMed ID: 19335782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.